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disease in female breast cancer survivors: systematic review
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ABSTRACT
Objective
To investigate the effect of endocrine therapies on a 
wide range of specific clinical cardiovascular disease 
outcomes in women with a history of non-metastatic 
breast cancer.
Design
Systematic review and meta-analysis of randomised 
controlled trials and observational studies.
Data sOurces
Medline and Embase up until June 2018.
eligibility criteria fOr selecting stuDies
Studies were included if they investigated the risk of 
a specific cardiovascular disease outcome associated 
with use of either tamoxifen or an aromatase inhibitor, 
or compared the two treatments, in women with a 
history of non-metastatic breast cancer.
appraisal anD Data extractiOn
Relevant studies were originally identified and results 
extracted by one researcher, with a full replication of 
the study identification process by a combination of 
two other researchers. The Cochrane Collaboration’s 
tool for assessing risk of bias was used to assess risk 
of bias in randomised controlled trials, and this tool 
was adapted to assess risk of bias in observational 
studies.
results
26 studies were identified, with results for seven 
specific cardiovascular disease outcomes (venous 
thromboembolism, myocardial infarction, stroke, 
angina, heart failure, arrhythmia, and peripheral 
vascular disease). Results suggested an increased 
risk of venous thromboembolism in tamoxifen users 
compared with both non-users and aromatase 
inhibitor users. Results were also consistent with 
a higher risk of the vascular diseases myocardial 
infarction and angina in aromatase inhibitor users 
compared with tamoxifen users, but there was also 
a suggestion that this may be partly driven by a 
protective effect of tamoxifen on these outcomes. Data 
were limited, and evidence was generally inconsistent 
for all other cardiovascular disease outcomes.
cOnclusiOn
This review has collated substantial randomised 
controlled trial and observational evidence on the 
effect of endocrine therapies on several specific 
cardiovascular disease outcomes including venous 
thromboembolism and myocardial infarction, 
progressing knowledge. Although the choice of 
aromatase inhibitor or tamoxifen will primarily be 
based on the effectiveness against the recurrence of 
breast cancer, this review shows that the individual 
patient’s risk of venous or arterial vascular disease 
should be an important secondary consideration.
systematic review registratiOn
Prospero CRD42017065944.
Introduction
Endocrine therapies—namely, tamoxifen and 
aromatase inhibitors—reduce the risk of reoccurrence 
of breast cancer in patients diagnosed as having 
oestrogen receptor and/or progesterone receptor 
positive breast cancer following surgery (adjuvant 
treatment). The efficacy of tamoxifen, irrespective of 
menopausal status, has been confirmed in several 
randomised controlled trials,1 but UK guidelines were 
changed in 2006 to reflect the evidence that aromatase 
inhibitors are more efficacious in postmenopausal 
women.2 Concerns exist that endocrine therapies 
could increase the risk of cardiovascular disease—for 
example, through suppression of the cardiovascular 
protective effects of oestrogens.3 With improved 
survival after breast cancer, cardiovascular disease 
has become an increasingly important source of long 
term morbidity and mortality among breast cancer 
survivors.4 Understanding any associations between 
treatment of cancer and risk of cardiovascular disease 
is critical to inform prevention and management of 
adverse cardiovascular effects.
Several systematic reviews and meta-analyses 
of randomised controlled trials,2  5-9 and some non-
systematic reviews,10-13 have compared cardiotoxicities 
of endocrine therapies in breast cancer survivors 
(systematic reviews summarised in appendix  1). 
Several reported a higher incidence of adverse 
cardiovascular disease outcomes in users of aromatase 
WhAT IS AlReAdy knoWn on ThIS TopIC
Several meta-analyses of randomised controlled trials have reported the effect 
of endocrine therapies used in adjuvant treatment of breast cancer on the risk of 
composite cardiovascular disease outcomes
However, these reviews have not reported the effect of endocrine therapies on a 
range of clinically specific cardiovascular diseases
They have also omitted the growing body of evidence from observational studies, 
which often include large study populations in real world settings, as well as 
longer follow-up
WhAT ThIS STudy AddS
Observational evidence is generally consistent with trial evidence reporting an 
increased risk of venous thromboembolism in tamoxifen users compared with 
both non-users and aromatase inhibitor users
Evidence also exists of a higher risk of vascular disease in aromatase inhibitor 
users compared with tamoxifen users, which may be driven by a protective effect 
of tamoxifen
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inhibitors compared with tamoxifen, but results were 
not universally in agreement. The most recent meta-
analysis suggested a 19% higher risk of a composite 
of cardiovascular disease outcomes, excluding 
venous thromboembolism, in users of aromatase 
inhibitors compared with tamoxifen but hypothesised 
that this may reflect the cardioprotective effects of 
tamoxifen.5 Important limitations of the randomised 
controlled trial evidence included in these reviews 
may have contributed to the mixed picture, including 
high degrees of trial heterogeneity, limited power 
of individual trials, and inconsistent reporting of 
cardiovascular disease outcomes in trials focusing on 
anticancer effects. Previous reviews have also mainly 
reported results for composite cardiovascular disease 
outcomes rather than clinically specific cardiovascular 
diseases and omitted the growing body of evidence 
from observational studies on this topic, which often 
include large study populations in real world settings 
and longer follow-up.
The aims of this systematic review were to identify 
and summarise both randomised controlled trial 
and observational evidence on associations between 
endocrine therapies and a wide range of specific 
clinical cardiovascular disease outcomes in women 
with a history of early breast cancer, to describe 
the differences between findings from randomised 
controlled trials and real world observational studies, 
and to assess the quality and potential for bias in 
studies investigating this topic.
Methods
inclusion criteria
We included randomised controlled trials and 
observational studies if they carried out at least 
one analysis assessing the risk of a specific 
cardiovascular disease outcome associated with 
tamoxifen, aromatase inhibitors, or a comparison 
of the two treatments after the diagnosis of non-
metastatic breast cancer in women. The outcomes of 
interest were vascular disease—angina, myocardial 
infarction, revascularisation procedures, sudden 
cardiac arrest, stroke (haemorrhagic and ischaemic), 
and peripheral vascular disease; myocardial disease—
cardiomyopathy, heart failure, and arrhythmia; venous 
thromboembolism; pericarditis; and valvular heart 
disease.
We excluded studies if only a composite 
cardiovascular disease outcome or mortality from 
cardiovascular disease was assessed, only women 
with metastatic breast cancer were included in the 
study population, or the study exclusively analysed 
temporal differences for the same treatment on the risk 
of cardiovascular disease. We also excluded previous 
systematic reviews and meta-analyses exploring the 
cardiotoxicities of systemic breast cancer therapies 
(specifically endocrine therapies), but we included 
relevant randomised controlled trials captured in these 
reviews that were not captured in the main search, 
along with any more recent or previously unidentified 
trials. We also manually searched all randomised 
controlled trials of endocrine therapy for breast cancer 
published since the most recent systematic review to 
ensure that more recent trial papers were not missed.
search strategy and data extraction
We used the health and medical literature databases 
Medline and Embase to search for relevant publications. 
The searches were performed in June 2018. Conference 
abstracts, grey literature, and unpublished studies 
were not included. To identify all relevant literature, 
the search strategy for each database included a 
comprehensive list of both index and free text terms for 
breast cancer, endocrine therapies, and cardiovascular 
disease. The full search terms used are outlined in 
appendix 2. We manually searched the reference lists 
of all studies identified in the search to further identify 
relevant studies that were originally missed.
We extracted relative risks, odds ratios, or hazard 
ratios if they were calculated in the paper. We 
calculated the relative risk and 95% confidence 
interval if effect estimates were not presented but 
data on the number of outcome events in follow-up 
allowed their calculation. We also collated information 
on the country in which the study was based, study 
type (randomised controlled trial or observational), 
data source (if an observational study), study design 
(if an observational study), age of included patients, 
inclusion criteria, exclusion criteria, intervention 
arm (and number of patients in the arm), reference 
arm (and number of patients in the arm), primary 
endpoint, cardiovascular disease outcome(s) assessed, 
mean/median follow-up time, statistical methods, and 
covariates adjusted for.
One researcher (AM) identified all relevant studies 
from the original literature search and extracted 
the results of these studies. The study identification 
process was repeated by a combination of two other 
authors (RF and HS). The extraction table was also 
piloted on two studies by two researchers (AM and RF) 
to check reproducibility of key information.
risk of bias assessment
We used the Cochrane Collaboration’s tool for assessing 
risk of bias to assess risk of bias in randomised 
controlled trials.14 We then adapted this tool to produce 
separate risk of bias assessments for cohort and case-
control studies, with domains for each type of bias that 
could be encountered within both observational study 
designs (appendices 3 and 4).
statistical analysis
We organised seven possible comparisons between 
study arms/exposures during follow-up into three 
groups defined a priori to aid presentation. Group 1 
included the direct comparison between aromatase 
inhibitor use and tamoxifen use during follow-up. 
Group 2 included three comparisons, all characterised 
as addition of tamoxifen in the intervention arm during 
follow-up (tamoxifen versus placebo, tamoxifen versus 
no tamoxifen, sequenced therapy (tamoxifen followed 
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by aromatase inhibitor or vice versa) versus aromatase 
inhibitor). Group 3 also included three comparisons, 
with addition of aromatase inhibitor in the intervention 
arm during follow-up (aromatase inhibitor versus 
placebo, aromatase inhibitor versus no aromatase 
inhibitor, sequenced therapy versus tamoxifen).
To investigate differences in study findings for the 
same cardiovascular disease outcome, study type 
(randomised controlled trial or observational), and 
comparison (for the seven possible comparisons 
outlined above), we used I2 tests and P values for 
Cochrane Q tests to assess heterogeneity.15 We 
considered an I2 value of above 25% to be evidence 
of between study heterogeneity.16 We used a fixed 
effect meta-analysis to combine individual study 
effects estimates if there was more than one study and 
no evidence of heterogeneity within cardiovascular 
disease outcome, study type, and comparison strata. If 
we found evidence of between study heterogeneity, we 
assessed studies within the same strata for differences 
in study population, statistical analysis methods, 
and covariate adjustments, but they were not meta-
analysed. For the purposes of exploring heterogeneity 
and meta-analysing results, we considered randomised 
controlled trials and observational studies separately. 
We used a test for funnel plot asymmetry to examine 
publication bias if there were more than 10 studies 
within the same cardiovascular disease outcome, 
study type, and comparison strata.17
patient involvement
No patients were involved in setting the research 
question or the outcome choices, nor were they involved 
in developing plans for design or implementation 
of the study. No patients were asked to advise on 
interpretation or writing up of results.
Results
Figure 1 outlines the screening process. We included 
26 studies after applying the inclusion and exclusion 
criteria.18-44 Six previous meta-analyses or systematic 
reviews of randomised trials were also identified.2  5-9 
We identified 12 individual randomised controlled 
trials that met the inclusion criteria from within these 
meta-analyses and included them in our review. 
One further study was identified from scanning the 
reference lists of the other papers. The final 26 included 
studies consisted of 15 randomised controlled trials 
and 11 observational studies. Table 1 summarises 
the included studies, with a more detailed breakdown 
in appendix 5. There were minimal discrepancies 
between authors in the duplication of the search 
strategy.
The most commonly investigated outcomes were 
venous thromboembolism (n=15), myocardial 
infarction (n=14), and stroke (n=12). Arrhythmia and 
peripheral vascular disease were each investigated 
in a single study. Studied outcomes did not 
include revascularisation, sudden cardiac arrest, 
cardiomyopathy, pericarditis, or valvular heart disease.
bias assessment
Table 2 and table 3 show an overview of the risk of bias 
assessment of all randomised controlled trials and 
observational studies, with more detailed information 
in appendices 6 and 7. The main problem when 
assessing bias in randomised controlled trials was the 
incomplete reporting of methods, which in many cases 
made fully judging whether studies were prone to 
certain biases impossible. Three of the 15 randomised 
controlled trials were open label trials, and so were at 
higher risk of performance bias. Only one randomised 
controlled trial reported sufficient information to 
assess potential selective reporting of cardiovascular 
disease outcomes.
All observational studies had at least one domain 
categorised as being at high risk of bias. Six out 
of the 11 studies had a high risk of bias for the 
methods used to define exposure, which was mostly 
owing to not requiring women to have a minimum 
exposure period or several prescriptions before 
being categorised as exposed, raising the possibility 
of exposure misclassification. Risk of bias due to 
residual confounding was also present across both 
cohort and case-control observational studies. Seven 
studies adjusted only for basic risk factors and did not 
consider cardiovascular disease related treatment, 
cancer severity at diagnosis, or other cancer treatments 
such as chemotherapy or biological therapy.
We did not assess publication bias because no 
cardiovascular disease outcome, study type, or 
comparison strata included more than 10 studies.
Studies identied from database search (n=1346)
Studies for which abstract was screened (n=284)
Studies for which full text was screened (n=79)
Studies included in systematic review (n=26)
Excluded (n=1062):
  Duplicates (n=59)
  Based on title: Clinical guidelines, lecture abstract,
    mouse models, metastatic breast cancer, trial
    protocol, male breast cancer, review/meta
    analysis, commentary, case study (n=1003)
Excluded based on abstract:
Only temporal eects, biomarker outcomes,
treatment in breast cancer prevention (n=205)
Full text did not meet inclusion criteria:
Composite outcome, mortality outcomes (n=60)
Meta-analyses/systematic reviews (n=6)
Randomised controlled trials identied from
meta-analyses/systematic reviews (n=12)
Further studies identied
from reference lists (n=1)
fig 1 | flow diagram of screening process of studies 
included in systematic review. rct=randomised 
controlled trial
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vascular disease
Figure 2 shows relative risks and 95% confidence 
intervals for all vascular disease outcomes. Three 
of the four randomised controlled trials and one 
observational study that directly compared aromatase 
inhibitors with tamoxifen showed increased risks 
of myocardial infarction in the aromatase inhibitor 
group, with relative risks ranging from 1.50 to 
2.29.18  30  32  38  44 However, the effect was statistically 
significant only in the observational study and one 
randomised controlled trial. Most (five out of eight) 
of the studies that explored the addition of tamoxifen 
observed a lower risk of myocardial infarction in 
the tamoxifen group,19  22  24  26  27  35  36  43 including 
one trial and two observational studies that found 
a significantly protective relative risk. Although 12 
studies explored the risk of stroke in users of endocrine 
therapy,21  24  26  27  33  38-44 the picture was much more 
mixed and included estimates in both directions. 
Three of the five observational studies that compared 
tamoxifen use with non-tamoxifen use suggested a 
decreased risk of stroke in tamoxifen users.21  24  26  43 
Furthermore, the results for angina were consistent 
with patterns seen for myocardial infarction, but only 
four studies explored this outcome.19 28 41-43 However, 
one randomised controlled trial reported an increased 
risk of angina in aromatase inhibitor users compared 
with placebo users (relative risk 1.35, 95% confidence 
interval 1.17 to 1.56). Finally, only one inconclusive 
randomised controlled trial explored the risk of 
peripheral vascular disease in aromatase inhibitor 
users compared with tamoxifen users.30
myocardial disease
Figure 3 shows relative risks and 95% confidence 
intervals for all myocardial disease outcomes. One 
randomised controlled trial suggested an increased 
risk of heart failure in aromatase inhibitor users 
compared with tamoxifen users (aromatase inhibitor 
versus tamoxifen: relative risk 1.20, 1.04 to 1.38),39 
but this was not replicated in an observational cohort 
study.42 A fixed effects meta-analysis based on two 
observational studies pointed towards a decreased risk 
of heart failure in tamoxifen users compared with non-
users, albeit with a wide confidence interval (relative 
risk 0.84, 0.65 to 1.07; I2=0; Cochrane T test P=0.33; 
appendix 8),42 43 which was replicated in a randomised 
controlled trial.36 One inconclusive study explored the 
risk of arrhythmia in tamoxifen users compared with 
non-users.36
venous thromboembolism
Figure 4 shows relative risks and 95% confidence 
intervals for all venous thromboembolism outcomes. 
Five out of six randomised controlled trials directly 
comparing the risk of venous thromboembolism in 
aromatase inhibitor users versus tamoxifen users 
estimated large protective relative risks ranging 
from 0.25 to 0.61,28  29  32  38  39  44 with one further 
randomised controlled trial finding no association 
(I2=0%, Cochrane Q test P=0.70, fig 4). A fixed effects 
meta-analysis (appendix 9) suggested a decreased 
risk of thromboembolic events in aromatase inhibitor 
users compared with tamoxifen users (relative risk 
0.61, 0.58 to 0.63). Five randomised controlled trials 
in which the key difference between treatment arms 
was use of tamoxifen reported an increased risk of 
thromboembolic events in the tamoxifen arm, with 
relative risks ranging from 1.06 to 4.49.27  31  35-37 
The three randomised controlled trials comparing 
tamoxifen with placebo reported an increased risk 
of venous thromboembolism in tamoxifen users, but 
with 95% confidence intervals that crossed the null 
association (I2=45%; Cochrane Q test P=0.16).31  35  37 
A further three observational studies compared the 
risk of thromboembolic events in tamoxifen users 
and non-tamoxifen users (I2=92%, Cochrane Q test 
P=0.00).20  23  25 Two found large increased risks in 
tamoxifen users (relative risks 2.40, 1.60 to 3.40, 
table 1 | Overview of characteristics of studies included 
in systematic review. values are numbers (percentages)
value (n=26)
study type
Randomised controlled trial 15 (58)
Observational 11 (42)
 Case-control 4 (15)
 Cohort 7 (27)
country/region
North America 8 (31)
 Canada 2 (8)
 USA 5 (19)
 USA and Canada 1 (4)
Europe 11 (42)
 Denmark 2 (8)
 Germany 1 (4)
 Italy 1 (4)
 Scotland 1 (4)
 Sweden 1 (4)
 UK 3 (12)
 Europe-wide 2 (8)
Rest of world 3 (12)
 Taiwan 2 (8)
 Egypt 1 (3)
International 4 (15)
study population
<80 years old 1 (4)
<70 years old 1 (4)
35-70 years old 1 (4)
45-69 years old 2 (8)
All women 7 (27)
Postmenopausal 13 (50)
Premenopausal 1 (4)
year of study
Before 2000 4 (15)
2000-10 13 (50)
After 2010 9 (35)
Outcomes*
Vascular disease
 Myocardial infarction 14 (54)
 Stroke 12 (46)
 Angina 4 (15)
 Peripheral vascular disease 1 (4)
Myocardial disease
 Heart failure 4 (15)
 Arrhythmia 1 (4)
Thromboembolic events 15 (58)
*Individual studies often included more than one outcome.
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and 7.10, 1.50 to 33.0023  25), and one reported no 
difference in risk of thromboembolic events (0.94, 
0.78 to 1.1320), although this study had a high risk 
of bias owing to how exposure was defined. One 
randomised controlled trial reported an increased risk 
of thromboembolic events in aromatase inhibitor users 
compared with those given a placebo (relative risk 
1.84, 1.11 to 3.04).41
discussion
Among 26 studies providing data on seven specific 
cardiovascular disease outcomes, we found 
consistent evidence of an increased risk of venous 
thromboembolism in tamoxifen users compared 
with non-users in both randomised controlled trials 
and observational studies, with a correspondingly 
decreased risk of venous thromboembolism when 
aromatase inhibitor users were compared directly with 
tamoxifen users. However, the direct effect of aromatase 
inhibitors on venous thromboembolism was less clear, 
as only a single randomised controlled trial compared 
aromatase inhibitor with placebo, finding an increased 
risk in aromatase inhibitor users. The evidence on the 
effects of endocrine therapies on vascular disease risks 
was mixed: most studies were consistent with a higher 
risk of myocardial infarction and angina in aromatase 
inhibitor users compared with tamoxifen users, and 
there was a suggestion that this may be partly driven 
by a protective effect of tamoxifen on these outcomes; 
inconsistent results were found for the associations 
with stroke. Of the few studies assessing other 
outcomes, data were limited and very mixed patterns 
were observed, making drawing conclusions difficult.
Quality and limitations of evidence
Thirteen of the 15 randomised controlled trials 
identified disease-free survival as the primary outcome 
of the study, whereas all observational studies 
identified either one or several specific cardiovascular 
disease events as their primary outcome. Women 
with previous cardiovascular disease were therefore 
excluded from many observational studies but 
not from randomised controlled trials. Overall, 
women included in the randomised controlled trial 
populations were therefore likely to be at a higher 
absolute risk of cardiovascular disease during follow-
up, which would be problematic only if the prevalence 
of cardiovascular disease at baseline was different 
between the treatment arms. In theory, randomisation 
should result in an equal prevalence of cardiovascular 
disease at baseline between arms. However, many 
included studies did not report information on 
randomisation and concealment of allocation, 
meaning that selection bias in relation to prevalent 
cardiovascular disease at the point of randomisation 
cannot be disregarded. Randomised controlled trials 
also did not report data on cardiovascular disease 
risk at baseline, but participants in trials are likely 
to be healthier than the general population and thus 
may have had less previous cardiovascular disease. As 
table 2 | risk of bias assessment overview: observational studies
paper study design exposure definition Outcome/case definition control selection confounding missing data censoring
Abdel-Qadir 2016 Cohort High High NA Low Unknown Low
Chen 2014 Cohort High Low NA High Unknown Low
Haque 2016 Cohort High Low NA Low Low Low
Hernandez 2008 Cohort Unknown Low NA Low Unknown Low
Hernandez 2009 Cohort Unknown Low NA Low High Low
Ligibel 2012 Cohort High Low NA High Unknown Low
Yang 2014 Cohort High Low NA High Unknown Unknown
Bradbury 2005 Case-control High High Low High Low NA
Geiger 2004 Case-control Low Low Low High High NA
Geiger 2005 Case-control Low Low Low High High NA
Meier 1998 Case-control Low Low Low High High NA
NA=not applicable
table 3 | risk of bias assessment overview: randomised controlled trials
paper random sequence generation allocation concealment blinding incomplete outcome data selective reporting Other sources of bias
Bliss 2012 Low Unknown Low Low Low Low
Boccardo 2006 Unknown Unknown Unknown Low Unknown Low
Coombes 2007 Low Unknown Low Low Unknown Low
Fisher 1999 Unknown Unknown Unknown Low Unknown Low
Fisher 2001 Low Unknown Unknown Low Unknown Low
Forbes 2008 Low Low Unknown Unknown Unknown Low
Jakesz 2005 Low Low High Unknown Unknown Low
Kaufmann 2007 Low Low Unknown Low Unknown Low
McDonald 1995 Unknown Unknown Unknown Unknown Unknown Low
Colleoni 2011 Low Unknown Low Low Unknown Low
Rutqvist 1993 Unknown Unknown Unknown Low Unknown Low
van de Velde 2001 Low Low High Unknown Unknown Low
Abo-Touk 2010 Low Unknown Unknown Low Unknown Low
Goss 2005 Low Unknown Low Low Unknown Low
Pagani 2014 Low Unknown High Low Unknown Low
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Myocardial infarction
  Aromatase inhibitor v tamoxifen
    Forbes 200838
    Jakesz 200532
    Coombes 200730
    Pagani 201444
    Abdel-Qadir 201618
  Addition of tamoxifen
    McDonald 199527
    van de Velde 201136
    Rutqvist 199335
    Bradbury 200519
    Yang 201426
    Hernandez 200843
    Ligibel 201224
    Geiger 200522
  Addition of aromatase inhibitor
    Goss 200541
    Ligibel 201224
Stroke
  Aromatase inhibitor v tamoxifen
    Pagani 201444
    Forbes 200838
    Colleoni 201139
    Abo-Touk 201040
    Kaufmann 200733
    Haque 201642
  Addition of tamoxifen
    McDonald 199527
    Yang 201426
    Ligibel 201224
    Hernandez 200843
    Geiger 200421
      Haque 201642
  Addition of aromatase inhibitor
    Goss 200541
    Ligibel 201224
Angina
  Aromatase inhibitor v tamoxifen
    Bliss 201228
  Addition of tamoxifen
    Bradbury 200519
    Hernandez 200843
  Addition of aromatase inhibitor
    Goss 200541
Peripheral vascular disease
  Aromatase inhibitor v tamoxifen
    Coombes 200730
0.99 (0.62 to 1.42)
1.50 (0.17 to 17.90)
1.63 (0.92 to 2.88)
2.29 (1.56 to 3.03)
2.02 (1.16 to 3.53)
0.49 (0.26 to 0.95)
0.79 (0.57 to 1.09)
0.83 (0.45 to 1.56)
0.20 (0.10 to 0.80)
0.22 (0.07 to 0.70)
1.00 (0.67 to 1.60)
1.04 (0.73 to 1.49)
1.20 (0.70 to 1.90)
0.82 (0.55 to 1.22)
0.90 (0.65 to 1.25)
0.46 (0.37 to 1.29)
0.59 (0.47 to 0.68)
1.18 (1.08 to 1.30)
2.00 (0.11 to 35.44)
3.05 (0.32 to 29.18)
0.82 (0.63 to 1.06)
1.15 (0.63 to 2.13)
0.52 (0.35 to 0.78)
0.78 (0.50 to 1.20)
0.81 (0.44 to 1.50)
1.00 (0.60 to 1.60)
1.03 (0.71 to 1.54) 
1.14 (0.89 to 1.45)
0.71 (0.43 to 1.03)
1.37 (0.92 to 2.05)
0.40 (0.20 to 0.80)
0.88 (0.65 to 1.20)
1.35 (1.17 to 1.56)
1.25 (0.68 to 2.29)
6186
3224
4724
4643
9350
1312
9766
2365
7263
3960
16 289
88 052
396
5170
88 052
4643
6186
4922
120
1040
13 273
1312
3960
88 052
16 289
532
13 273
5170
88 052
4599
7263
16 289
5170
4724
0.125 0.25 0.5 1 2 4 8
Paper Relative risk
(95% CI)
Relative risk
(95% CI)
No
AI v tamoxifen
AI v tamoxifen
AI v tamoxifen
AI v tamoxifen
AI v tamoxifen
Tamoxifen v no tamoxifen
Tamoxifen → AI v AI
Tamoxifen v placebo
Tamoxifen v no tamoxifen
Tamoxifen v no tamoxifen
Tamoxifen v no tamoxifen
Tamoxifen v no tamoxifen
Tamoxifen v no tamoxifen
AI v placebo
AI v no AI
AI v tamoxifen
AI v tamoxifen
AI v tamoxifen
AI v tamoxifen
AI v tamoxifen
AI v tamoxifen
Tamoxifen v no tamoxifen
Tamoxifen v no tamoxifen
Tamoxifen v no tamoxifen
Tamoxifen v no tamoxifen
Tamoxifen v no tamoxifen
Tamoxifen v no tamoxifen
AI v placebo
AI v no AI
AI v tamoxifen
Tamoxifen v no tamoxifen
Tamoxifen v no tamoxifen
AI v placebo
AI v tamoxifen
Comparison
68.7
68.7
68.7
68.7
NA
NA
NA
NA
74.8
74.8
74.8
74.8
74.8
NA
NA
92.1
92.1
92.1
92.1
92.1
NA
NA
41.9
41.9
41.9
41.9
41.9
NA
NA
NA
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fig 2 | estimated relative risk (95% ci) for studies examining use of endocrine therapy and risk of specific vascular diseases, with  
corresponding i2 tests, Q tests, and assessment of bias according to prespecified criteria. *p value. ai=aromatase inhibitor; na=not applicable
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people with previous cardiovascular disease are likely 
to be underrepresented in randomised controlled 
trials, and are excluded from observational studies, 
the evidence on the association between endocrine 
therapies and risk of cardiovascular disease in this 
population remains limited. Furthermore, as the 
randomised controlled trials were mainly designed 
to assess disease-free survival, they were not always 
adequately powered to detect relative differences in 
the risk of clinical cardiovascular disease outcomes 
between treatment arms.
Definitions of cardiovascular disease outcomes were 
generally poorly recorded in the included studies. 
Between study variation could therefore exist in the 
measurement or coding of cardiovascular disease 
outcomes. Most oncology trials use the CTCAE criteria 
for adverse events, which have definitions that do 
not align with definitions in cardiology guidelines, 
although even the latter have variability. Furthermore, 
as observational studies rely on definitions of outcomes 
suggested by researchers and clinicians, differences 
in coding of outcomes could be a further source of 
heterogeneity in the observational studies. Without 
access to the outcome definitions and code lists used in 
these studies, fully understanding the extent to which 
the differences are problematic is challenging.
explanation of key findings
A biological rationale exists for the use of aromatase 
inhibitors increasing the risk of cardiovascular 
disease outcomes, as they reduce oestrogen 
concentrations and therefore the oestrogen-mediated 
protective effects on cardiovascular disease, such 
as regulation of serum lipid metabolism, increasing 
vasodilation, and inhibition of the development of 
atherosclerosis.45 Aromatase inhibitors could also 
increase the risk of hyperlipidaemia.36 Evidence from 
randomised controlled trials suggests that tamoxifen 
has cardioprotective effects by decreasing lipid 
concentrations.46 47 This systematic review postulates 
that some evidence exists for aromatase inhibitor users 
having an increased risk of myocardial infarction, 
relative to women treated with tamoxifen. However, 
whether this is driven by a decreased risk of myocardial 
infarction in tamoxifen users or an increased risk in 
aromatase inhibitor users is unclear, as results on the 
individual effects of tamoxifen and aromatase inhibitor 
are inconclusive.
We found evidence of heterogeneity between all 
four strata of observational studies exploring the same 
exposure and outcome (risk of myocardial infarction, 
stroke, angina, and venous thromboembolism with 
the addition of tamoxifen), which was potentially 
driven by the differences in study populations, 
statistical techniques used, and covariates adjusted for 
(appendix 5). For example, one cohort and one case-
control study reported an increased risk of venous 
thromboembolism in tamoxifen users compared with 
non-tamoxifen users in European study populations 
(Denmark and the UK, respectively), whereas a study 
in Taiwan reported no evidence of a difference in risk. 
More broadly, as this systematic review attempted to 
cover a wide range of clinical cardiovascular disease 
outcomes, some included observational studies 
focused on one cardiovascular disease outcome, 
whereas others covered a broad range of cardiovascular 
disease outcomes. Different statistical techniques and 
covariate adjustments were therefore needed. The effect 
of this heterogeneity between studies was witnessed in 
the varying relative risks reported within these strata of 
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fig 3 | estimated relative risk (95% ci) for studies examining use of endocrine therapy and risk of specific myocardial diseases, with corresponding i2 
tests, Q tests and assessment of bias according to prespecified criteria
 o
n
 19 O
ctober 2018 by guest. Protected by copyright.
http://www.bmj.com/
BM
J: first published as 10.1136/bmj.k3845 on 8 October 2018. Downloaded from 
RESEARCH
8 doi: 10.1136/bmj.k3845 | BMJ 2018;363:k3845 | the bmj
observational studies, which could be either a product 
of genuine discrepancies in risks between contrasting 
populations or the effect of residual confounding and 
different statistical techniques.
comparison with other studies
The addition of observational studies in this review 
allowed comparison of results between real world 
populations and randomised controlled trials that 
generally use homogeneous study populations. 
Overall, we mostly found agreement in the direction 
of effect between randomised controlled trials and 
observational studies, but several observational studies 
reported more extreme effect estimates in comparison 
with randomised controlled trials (the risk of myocardial 
infarction with the addition of tamoxifen and the risk 
of venous thromboembolism with the addition of 
tamoxifen). However, these observational studies all 
had a high risk of bias in at least two assessment of 
bias categories. Including observational studies also 
enabled further evidence to be gathered where little or 
no evidence from randomised controlled trials existed. 
For example, we identified six observational analyses 
of vascular endpoints finding good or strong evidence 
for a higher risk for aromatase inhibitor compared 
with tamoxifen or a lower risk for tamoxifen compared 
with no tamoxifen. Most randomised controlled trial 
analyses were underpowered to detect differences in 
vascular endpoints, with only three finding similar 
clear evidence despite several others being suggestive 
of associations in the same direction.
We grouped comparisons on the basis of the drug 
women were given at the beginning of follow-up. For 
example, in several randomised controlled trials, 
women were given two to three years of tamoxifen 
before being randomised to either aromatase inhibitor 
or the continuation of tamoxifen for a further two to 
three years, with follow-up beginning at the point 
of randomisation. We classed these as a direct 
comparison of aromatase inhibitor versus tamoxifen, 
whereas previous reviews classed these comparisons 
as sequenced therapy versus tamoxifen alone. As all 
women had had the same treatment regimen before 
randomisation, classing these as aromatase inhibitor 
versus tamoxifen was a reasonable comparison to 
make.
The most recent meta-analysis by Khosrow 
concluded that randomised controlled trials directly 
comparing aromatase inhibitors with tamoxifen 
suggest that aromatase inhibitors are associated with 
an increased risk of cardiovascular events, but the 
cardioprotective effects of tamoxifen may account 
for this increased risk.5 However, Khosrow et al 
used composite cardiovascular disease endpoints 
(excluding venous thromboembolism), which are 
defined slightly differently within each trial. We 
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fig 4 | estimated relative risk (95% ci) for studies examining use of endocrine therapy and risk of venous thromboembolism, with corresponding i2 
tests, Q tests, and assessment of bias according to prespecified criteria
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stratified cardiovascular disease events into more 
specific outcomes and found a similar pattern for 
several vascular cardiovascular disease outcomes. 
The results for other cardiovascular disease outcomes 
including heart failure suggest a similar trend, but few 
studies have specifically explored these outcomes, 
so definite conclusions are unattainable. Like our 
study, that of Khosrow et al was inconclusive about 
the effects of endocrine therapy on cerebrovascular 
events. Another recent review by Rydén reported, 
with a high quality of evidence, that the risk of venous 
thromboembolism was higher in tamoxifen users than 
aromatase inhibitor users in randomised controlled 
trials.2 Our study agrees with these results but also 
shows that this may be accounted for by the increased 
risk in tamoxifen users.
strengths and limitations of this review
This study focused on individual clinical cardiovascular 
disease outcomes, excluding studies that reported 
composite outcomes. Understanding the effect of 
endocrine therapies on cardiovascular disease as a 
whole has several advantages, such as the potential 
to change the modifiable risk factors weight, smoking, 
statin use, and alcohol intake, which are present 
across all clinical cardiovascular diseases. However, 
understanding the effect of endocrine therapies on 
more specific clinical cardiovascular disease outcomes 
has the potential to enable clinicians to be targeted 
in their approach to preventing these outcomes in 
breast cancer survivors. The only composite outcome 
that we explored was venous thromboembolism, 
as some studies in this group included only deep 
vein thrombosis outcomes whereas others also 
included pulmonary embolism within a venous 
thromboembolism outcome. However, this grouping is 
relevant owing to the clinical similarities of deep vein 
thrombosis and pulmonary embolism.
Some relevant studies may have been missed, as 
searches of literature database take into account 
only indexed key terms or words used in the title and 
abstract. Studies in which the secondary outcome was 
a cardiovascular disease would therefore not have 
been identified in the original search. For example, 
several randomised controlled trials that focused on 
anticancer efficacy do not mention cardiovascular 
diseases in the title, abstract, or indexed keywords. 
However, we searched multiple large databases, 
manually searched the included studies’ reference 
lists and relevant meta-analyses, and searched all 
endocrine therapy trials since the most recent meta-
analysis, which was an indirect way of identifying 
the aforementioned randomised controlled trials and 
made this review as comprehensive as possible within 
the restricted framework imposed by the literature 
databases.
implications of findings
This review establishes the need for clinical vigilance 
and possible preventive measures when prescribing 
endocrine therapies to women at risk of venous 
thromboembolism. Knowledge has also been 
progressed on the effects of endocrine therapies on 
the risk of vascular cardiovascular diseases, for which 
little evidence previously existed. However, we also 
showed that little or no evidence is available on the 
effect of endocrine therapies on several other specific 
cardiovascular disease outcomes, although substantial 
trial evidence outlines the effect on cardiovascular 
diseases generally. This is unlikely to be studied 
in future randomised controlled trials, so it is vital 
that large observational studies are carried out with 
details of baseline cardiovascular disease risk and 
drug treatment and clear definitions of cardiovascular 
disease events to fully understand the effects 
that endocrine therapies have on potentially fatal 
cardiovascular disease outcomes such as myocardial 
infarction, stroke, and heart failure.
conclusions
Overall, the totality of the randomised controlled trial 
and observational evidence suggests a decreased risk of 
venous thromboembolism in aromatase inhibitor users 
compared with tamoxifen users, which is probably 
accounted for by an increased risk in tamoxifen users. 
The evidence also suggests that tamoxifen may have 
a protective association with vascular cardiovascular 
diseases, which may drive the higher risk of these 
outcomes in aromatase inhibitor users when directly 
compared with tamoxifen users. The results for some 
cardiovascular disease outcomes is still a mixed 
picture, many of the existing studies are susceptible 
to various sources of bias, and cardiovascular disease 
outcomes collected in oncology trials are generally 
limited. Nevertheless, the addition of observational 
studies alongside randomised controlled trials has 
substantially increased the amount of evidence 
supporting these conclusions. However, further 
high quality evidence is still needed for several 
cardiovascular disease outcomes. Although choice 
of aromatase inhibitor or tamoxifen will primarily 
be based on the effectiveness against recurrence of 
breast cancer, the individual patient’s risk of venous 
or arterial vascular disease is an important secondary 
consideration, and the totality of evidence we present 
will thus help to inform prescribing.
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